文献速递性腺与生殖内分泌骨质疏松与钙磷/甲状旁腺

先天性低促性腺激素性性腺功能减退症男性的容积骨密度与微结构受损

Compromised Volumetric Bone Density and Microarchitecture in Men With Congenital Hypogonadotropic Hypogonadism.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

这项横断面研究纳入51例经基因分型的CHH/KS男性与40名健康志愿者,采用HR-pQCT、DXA及骨标志物评估骨结构。尽管长期激素治疗(10.8±6.8年),CHH/KS患者各部位aBMD更低,胫骨和桡骨皮质与小梁vBMD及皮质厚度降低,小梁微结构改变以小梁厚度下降为主;19岁前开始治疗对胫骨小梁骨量有显著优势。

要点

  • 长期激素治疗的CHH/KS男性仍存在aBMD和vBMD降低及骨微结构受损。
  • 小梁微结构改变以厚度下降为主,皮质骨面积减少。
  • 青春期前或青春期早期(19岁前)开始治疗与小梁骨量获益相关。

核心结论

  • CHH/KS男性尽管接受长期激素治疗,容积骨密度和骨微结构仍受损。
  • 青春期开始治疗与更好的小梁骨结局相关,强调早期诊断的重要性。

研究设计与样本

  • 横断面研究,在法国单中心三级学术医疗中心开展,纳入51例经基因分型的CHH/KS患者和40名健康志愿者。
  • 98%的CHH/KS男性曾接受睾酮和/或联合促性腺激素治疗。
  • 采用高分辨率外周定量CT、双能X线吸收法和血清骨标志物检测评估骨密度与微结构。

主要发现

  • CHH/KS与对照组在年龄、BMI、维生素D和PTH水平上无差异。
  • DXA显示CHH/KS男性腰椎、全髋、股骨颈和桡骨远端aBMD更低。
  • HR-pQCT显示胫骨和桡骨皮质及小梁vBMD降低、皮质厚度变薄。
  • 小梁微结构改变以小梁厚度下降为主,皮质骨面积更低,仅胫骨总面积和小梁面积更高。
  • 19岁前开始治疗在胫骨小梁骨体积/组织体积和小梁vBMD上具有显著优势。

临床怎么用

  • 对CHH/KS男性应关注骨健康,即使长期激素治疗也需评估骨密度和微结构。
  • 早期诊断并在青春期启动治疗可能改善小梁骨结局。

局限性

  • 横断面设计无法确定因果关系。
  • 样本量有限(51例患者和40名对照),来自单中心。
  • 未报告具体数值、置信区间和P值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Men with congenital hypogonadotropic hypogonadism (CHH) and Kallmann syndrome (KS) have both low circulating testosterone and estradiol levels. Whether bone structure is affected remains unknown. OBJECTIVE: To characterize bone geometry, volumetric density and microarchitecture in CHH/KS. METHODS: This cross-sectional study, conducted at a single French tertiary academic medical center, included 51 genotyped CHH/KS patients and 40 healthy volunteers. Among CHH/KS men, 98% had received testosterone and/or combined gonadotropins. High-resolution peripheral quantitative computed tomography (HR-pQCT), dual-energy x-ray absorptiometry (DXA), and measurement of serum bone markers were used to determine volumetric bone mineral density (vBMD) and cortical and trabecular microarchitecture. RESULTS: CHH and controls did not differ for age, body mass index, and levels of vitamin D and PTH. Despite long-term hormonal treatment (10.8 ± 6.8 years), DXA showed lower areal bone mineral density (aBMD) in CHH/KS at lumbar spine, total hip, femoral neck, and distal radius. Consistent with persistently higher serum bone markers, HR-pQCT revealed lower cortical and trabecular vBMD as well as cortical thickness at the tibia and the radius. CHH/KS men had altered trabecular microarchitecture with a predominant decrease of trabecular thickness. Moreover, CHH/KS men exhibited lower cortical bone area, whereas total and trabecular areas were higher only at the tibia. Earlier treatment onset (before age 19 years) conferred a significant advantage for trabecular bone volume/tissue volume and trabecular vBMD at the tibia. CONCLUSION: Both vBMD and bone microarchitecture remain impaired in CHH/KS men despite long-term hormonal treatment. Treatment initiation during adolescence is associated with enhanced trabecular outcomes, highlighting the importance of early diagnosis.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Ostertag A, Papadakis GE, Collet C, et al. Compromised Volumetric Bone Density and Microarchitecture in Men With Congenital Hypogonadotropic Hypogonadism. J Clin Endocrinol Metab. 2021. PMID: 33725720. doi:10.1210/clinem/dgab169

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。